Alzchem Group AG Approves €120 Million Investment in Creatine Capacity Expansion

Alzchem Group AG has announced the approval of a significant investment program valued at approximately €120 million. This initiative aims at expanding the capacity for creatine products, primarily targeting the health, nutrition, and pharmaceutical sectors. The investment will facilitate the construction of a new, increasingly automated production facility dedicated to creatine and its precursors.

This development is expected to occur in phases, with commissioning slated to begin in the latter half of 2027. Alzchem anticipates this expansion could generate additional annual sales in the low triple-digit million euro range, providing a substantial boost to earnings.